Friday, October 15, 2021

AbbVie drops Humira TV spend; Sanofi and Regeneron, Novo Nordisk step up on March pharma list


AbbVie’s Humira dropped out of the top spot on the pharma TV ad spenders list in March for the first time in years. Sanofi and Regeneron’s Dupixent took over the No. 1 position, followed by Novo Nordisk’s Rybelsus, leaving Humira in third place, according to data from real-time TV ad tracker iSpot.tv.

Humira’s downward move has been in the works; spending has been declining over the past few months as AbbVie re-directed some of Humira’s advertising budget from the longtime blockbuster to its new generation of immunology products in rheumatoid arthritis Rinvoq and psoriasis med Skyrizi.

AbbVie shifted advertising and salesforce resources to help boost the newer brands, Elaine Sorg, U.S. head of immunology, said in an interview with Fierce in November.

Other brands back on the list for March were Eli Lilly and Boehringer Ingelheim’s Type 2 diabetes drug Jardiance, and Johnson & Johnson’s psoriatic disease med Tremfya. While Jardiance continues its “on it” theme for patients around reducing heart attack and stroke risk, J&J debuted a new set of ads for its psoriatic arthritis and plaque psoriasis treatment.

The new Janssen division ad campaign takes a darker tone, aiming to reflect the real-life pain and struggles of patients with the conditions.

Overall spending may be normalizing after a spendy six months. Total spending for the top 10 pharma TV advertisers in March was $148 million, down from the February total of $165 million, but similar to last March’s $156 million and February’s $149 million, according to the iSpot.tv data.

However, with the advertising market in general still in flux thanks to the pandemic, it’s likely to take months or even longer to settle into any kind of new normal media buying—stay tuned. 

1. Dupixent

Movement: Up from No. 2
What is it? Regeneron and Sanofi’s IL-4 and IL-13-blocking anti-inflammatory
Total estimated spending: $24 million (up from $20.2 million in February)
Number of spots: Six (Three for atopic dermatitis, three for asthma)
Biggest-ticket ad: “Roll Up Your Sleeves: Shawn, Ore and Jennifer” (est. $10.2 million)

2. Rybelsus

Movement: Up from No. 3
What is it? Novo Nordisk oral GLP-1 diabetes med
Total estimated spending: $19.9 million (up from $18.7 million in February)
Number of spots: Three
Biggest-ticket ad: “Wake Up to Possibilities” (est. $10.9 million)

3. Humira

Movement: Down from No. 1
What is it? AbbVie anti-inflammatory drug
Total estimated spending: $19.6 million (down from $22.6 million in February)
Number of spots: Three (One for arthritis/psoriasis, two for ulcerative colitis/Crohn’s)
Biggest-ticket ad: “Body of Proof: Drums” with COVID help message (est. $7.6 million)

4. Trulicity

Movement: Up from No. 5 last month
What is it? Eli Lilly GLP-1 diabetes drug
Total estimated spending: $17.1 million (up slightly from $17 million in February)
Number of spots: Four
Biggest-ticket ad: “Truly Powerful: Hotel Manager” (est. $12 million)

5. Xeljanz

Movement: Up from No. 6 last month
What is it? Pfizer oral rheumatoid arthritis therapy
Total estimated spending: $13.6 million (down from $16.4 million in February)
Number of spots: Three
Biggest-ticket ad: “Pine Needles” (est. $7.7 million)

 

6. Rinvoq
Movement: 
Up from No. 9
What is it? AbbVie JAK inhibitor to treat RA
Total estimated spending: $12.2 million (up slightly from $12 million in February)
Number of spots: Three
Biggest-ticket ad: “Your Mission: Zipline” (est. $10.6 million)

7. Ozempic

Movement: Up from No. 10
What is it? Novo Nordisk GLP-1 diabetes med
Total estimated spending: $10.8 million (down from $11.7 million in February)
Number of spots: One
Biggest-ticket ad: “My Zone (featuring Billy Gardell)”

8. Jardiance
Movement: Not on the list last month
What is it? Eli Lilly and Boehringer Ingelheim SGLT2 diabetes treatment
Total estimated spending: $10.5 million

Number of spots: Five
Biggest-ticket ad: “Community Garden” (est. $4.9 million)

9. Enbrel

Movement: Down from No. 8
What is it? Amgen’s TNF inhibitor to treat autoimmune diseases
Total estimated spending: $9.98 million (down from $12.2 million in February)
Number of spots: One
Biggest-ticket ad: “Erin & Margo”

10. Tremfya

Movement: Not on the list last month
What is it? Johnson & Johnson IL-23 inhibitor psoriatic disease treatment
Total estimated spending: $9.97 million
Number of spots: Two
Biggest-ticket ad: “Emerge: $5 per dose” (est. $8 million)



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...